Home

William Aliski

CIK 1598426 · last filed 2024-06-11

William Aliski is a corporate insider who has filed 35 SEC Form 4 insider transactions across 3 companies since 2014. The most recent filing, for XFOR, was dated Jun 11, 2024. Across all open-market trades the lifetime net is −$6.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions. 26 SEC filings were submitted jointly with Ultragenyx Pharmaceutical Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.12M

Companies

3

Total Filings

35

Lifetime Open-Market Net

-$6.52M

Filer Profile

Reported Address
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO, CA 94949
Related Filers
Ultragenyx Pharmaceutical Inc. — 26 joint filings, latest 2021-06-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
XFOR Director 3,222 $3.40 $11.0K $0 6 2024-06-11
APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Director 0 $0.39 $0 $19.5K 7 2022-12-01
RARE Director 77,305 $14.40 $1.11M -$6.54M 22 2021-06-28

Recent Filings

35 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-06-11 XFOR Grant (A) +45,000 $0 EDGAR
2023-06-14 XFOR Grant (A) +45,000 $0 EDGAR
2022-12-01 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Mixed −8,500 $0 EDGAR
2022-06-27 XFOR Grant (A) +6,667 $0 EDGAR
2021-12-02 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Grant (A) — $0 EDGAR
2021-06-28 RARE Grant (A) +2,145 $0 EDGAR
2021-06-02 XFOR Grant (A) — $0 EDGAR
2021-02-23 RARE Mixed −1,000 -$383.7K EDGAR
2020-12-18 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Grant (A) — $0 EDGAR
2020-08-25 RARE Mixed — -$139.1K EDGAR
Showing 1–10 of 35
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.